Ratings Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
24.02 ^USD	+12.98%		+5.44%	-11.76%

May. 07	Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates	MT
May. 07	Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last few months, analysts have been revising downwards their earnings forecast.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BEAM THERAPEUTICS INC.	-11.76%	1.68B	C-
MODERNA, INC.	+26.37%	44.96B	B-
IQVIA HOLDINGS INC.	-1.01%	42.65B	B
LONZA GROUP AG	+46.00%	41.85B	A
CELLTRION, INC.	-5.31%	29.04B	C
ICON PUBLIC LIMITED COMPANY	+9.34%	26.08B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	19.03B	B
BIO-TECHNE CORPORATION	+6.23%	12.75B	B+
MEDPACE HOLDINGS, INC.	+26.99%	12.06B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.75B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes